MCID: PPT001
MIFTS: 51

Peptic Esophagitis

Categories: Gastrointestinal diseases

Aliases & Classifications for Peptic Esophagitis

MalaCards integrated aliases for Peptic Esophagitis:

Name: Peptic Esophagitis 12 15 17 71
Reflux Esophagitis 12 74 15
Gastro-Esophageal Reflux Disease with Esophagitis 71
Peptic Reflux Disease 12
Reflux Oesophagitis 12
Esophagitis, Peptic 43

Classifications:



External Ids:

Disease Ontology 12 DOID:13976
ICD9CM 34 530.11
MeSH 43 D004942
SNOMED-CT 67 54856001 57643001
UMLS 71 C0014869 C0677659

Summaries for Peptic Esophagitis

MalaCards based summary : Peptic Esophagitis, also known as reflux esophagitis, is related to duodenogastric reflux and gastrojejunal ulcer. An important gene associated with Peptic Esophagitis is ATP12A (ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit), and among its related pathways/superpathways are Folate Metabolism and Toll Comparative Pathway. The drugs Histamine and Famotidine have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and bone, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Wikipedia : 74 Gastroesophageal reflux disease (GERD), also known as acid reflux, is a long-term condition in which... more...

Related Diseases for Peptic Esophagitis

Diseases related to Peptic Esophagitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 426)
# Related Disease Score Top Affiliating Genes
1 duodenogastric reflux 31.1 GAST ATP4A ATP12A
2 gastrojejunal ulcer 31.0 ATP4A ATP12A
3 gastrointestinal ulceration, recurrent, with dysfunctional platelets 30.9 S100A8 PTGS2 HRH2 GAST
4 esophageal varix 30.6 ATP4A ATP12A ALB
5 superior mesenteric artery syndrome 30.6 ATP4A ATP12A
6 zollinger-ellison syndrome 30.5 HRH2 GAST ATP4A ATP12A
7 gastric dilatation 30.5 ATP4A ATP12A
8 constipation 30.5 PTGS2 GAST ATP4A ATP12A
9 cascade stomach 30.5 HRH2 ATP4A ATP12A
10 displacement of cardia through esophageal hiatus 30.5 GAST ATP4A ATP12A
11 pernicious anemia 30.4 GAST ATP4A ATP12A
12 volvulus of midgut 30.4 ATP4A ATP12A ALB
13 dyskinesia of esophagus 30.4 CCL26 ATP4A ATP12A
14 microinvasive gastric cancer 30.3 S100A8 GAST CDX2 ATP4A ATP12A
15 esophagitis 30.3 PTGS2 IL6 IL1B HRH2 GAST CYP2C19
16 mediastinitis 30.2 ATP4A ATP12A ALB
17 gastroduodenitis 30.2 S100A8 GAST ATP4A ATP12A
18 esophageal candidiasis 30.1 CYP2C19 CCL26 ATP4A ATP12A
19 ascaris lumbricoides infection 30.0 IL6 IL1B CXCL8
20 tropical sprue 29.9 LCT GAST ATP12A ALB
21 tonsillitis 29.9 IL6 IL1B CXCL8
22 bronchopneumonia 29.9 IL6 CXCL8 ALB
23 glossitis 29.8 IL6 IL1B ATP4A ATP12A
24 laryngitis 29.8 IL6 IL1B HRH2 ATP4A ATP12A
25 esophageal disease 29.8 CCL26 ATP4A ATP12A ALB
26 duodenum disease 29.8 S100A8 GAST CDX2 ATP4A ATP12A
27 esophagitis, eosinophilic, 1 29.8 EPC2 CCL26 ATP4A ATP12A
28 pharyngitis 29.8 PTGS2 IL6 IL1B CXCL8
29 hernia, hiatus 29.8 LCT LAT2 HRH2 GAST CYP2C19 CDX1
30 periodontitis 29.7 PTGS2 IL6 IL1B CXCL8
31 helicobacter pylori infection 29.7 S100A8 IL1B GAST CYP2C19 CXCL8
32 urticaria 29.6 PTGS2 IL6 HRH2
33 duodenitis 29.6 S100A8 GAST ATP4A ATP12A ALB
34 bronchitis 29.6 IL6 IL1B CXCL8 ALB
35 atrophic gastritis 29.6 S100A8 PTGS2 IL6 IL1B GAST CXCL8
36 fatty liver disease 29.6 IL6 IL1B CXCL8 ALB
37 barrett esophagus 29.6 PTGS2 IL6 GAST CDX2 CDX1
38 cerebral palsy 29.6 PTGS2 IL6 IL1B CXCL8
39 duodenal ulcer 29.5 S100A8 IL6 IL1B HRH2 GAST CYP2C19
40 non-alcoholic fatty liver disease 29.5 IL6 IL1B CXCL8 ALB
41 acute pancreatitis 29.5 IL6 IL1B CXCL8 ALB
42 peptic ulcer perforation 29.5 S100A8 HRH2 GAST ATP4A ATP12A ALB
43 lung disease 29.5 S100A8 IL6 IL1B CXCL8 ALB
44 sleep apnea 29.4 IL6 IL1B CXCL8 ALB
45 exanthem 29.4 IL6 CXCL8 ATP4A ATP12A ALB
46 interstitial cystitis 29.3 TRPV1 IL6 CXCL8
47 proteasome-associated autoinflammatory syndrome 1 29.3 PTGS2 IL6 IL1B CXCL8 ALB
48 active peptic ulcer disease 29.3 PTGS2 HRH2 CYP2C19 ATP4A ATP12A ALB
49 irritable bowel syndrome 29.2 TRPV1 OCLN IL6 CXCL8
50 gastroesophageal reflux 28.9 S100A8 PTGS2 IL6 IL1B HRH2 GAST

Comorbidity relations with Peptic Esophagitis via Phenotypic Disease Network (PDN): (show all 12)


Active Peptic Ulcer Disease Acute Cystitis
Anxiety Bronchitis
Deficiency Anemia Esophageal Disease
Esophagitis Gastroesophageal Reflux
Heart Disease Hypertension, Essential
Hypothyroidism Intermediate Coronary Syndrome

Graphical network of the top 20 diseases related to Peptic Esophagitis:



Diseases related to Peptic Esophagitis

Symptoms & Phenotypes for Peptic Esophagitis

MGI Mouse Phenotypes related to Peptic Esophagitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.96 ALB ATP12A ATP4A CDX1 CDX2 GAST
2 endocrine/exocrine gland MP:0005379 9.81 ALB ATP4A CDX1 CDX2 GAST HRH2
3 homeostasis/metabolism MP:0005376 9.77 ALB ATP12A ATP4A CDX2 EPC2 GAST
4 neoplasm MP:0002006 9.23 ALB ATP4A CDX2 GAST IL1B IL6

Drugs & Therapeutics for Peptic Esophagitis

Drugs for Peptic Esophagitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 51-45-6 774
2
Famotidine Approved Phase 4 76824-35-6 3325
3
Trimebutine Approved Phase 4 39133-31-8
4
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
7
Ondansetron Approved Phase 4 99614-02-5 4595
8
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
9
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
10
Pantoprazole Approved Phase 4 102625-70-7 4679
11
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
12
Calcium polycarbophil Approved Phase 4 126040-58-2
13
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
14
Zinc Approved, Investigational Phase 4 7440-66-6 32051
15
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
16
Citalopram Approved Phase 4 59729-33-8 2771
17
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
18
Ramosetron Investigational Phase 4 132036-88-5
19 Rebamipide Investigational Phase 4 90098-04-7
20 Mosapride Investigational Phase 4 112885-41-3
21
Polaprezinc Experimental Phase 4 107667-60-7
22 Indobufen Investigational Phase 4 63610-08-2
23 Histamine H2 Antagonists Phase 4
24 Histamine Antagonists Phase 4
25
Histamine Phosphate Phase 4 51-74-1 65513
26 Hormone Antagonists Phase 4
27 Hormones Phase 4
28 Protective Agents Phase 4
29 Anti-Inflammatory Agents Phase 4
30 glucocorticoids Phase 4
31 Fibrinolytic Agents Phase 4
32 Antipyretics Phase 4
33 Anti-Inflammatory Agents, Non-Steroidal Phase 4
34 Analgesics, Non-Narcotic Phase 4
35 Platelet Aggregation Inhibitors Phase 4
36 Cyclooxygenase Inhibitors Phase 4
37 Antirheumatic Agents Phase 4
38 Analgesics Phase 4
39 HIV Protease Inhibitors Phase 4
40
protease inhibitors Phase 4
41 Dermatologic Agents Phase 4
42 Central Nervous System Depressants Phase 4
43 Anti-Anxiety Agents Phase 4
44 Tranquilizing Agents Phase 4
45 Antipsychotic Agents Phase 4
46 BB 1101 Phase 4
47 Antipruritics Phase 4
48 Emetics Phase 4
49 Antineoplastic Agents, Hormonal Phase 4
50 Serotonin Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 327)
# Name Status NCT ID Phase Drugs
1 The Clinical Efficacy and Safety of Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
2 Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants. Unknown status NCT02806453 Phase 4
3 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
4 Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
5 Esomeprazole or Famotidine in the Management of Aspirin Related Non-ulcer Dyspepsia - a Double Blind Randomized Control Study Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
6 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
7 Comparative Study of Antiemetic Effect of Ramosetron With Combination of Ondansetron and Dexamethasone in Patients Undergoing Laparoscopic Cholecystectomy Unknown status NCT02803788 Phase 4 ramosetron, ondansetron, dexamethasone
8 Laparoscopic Nissen Fundoplication Combined With Posterior Gastropexy in Surgical Treatment of Gastroesophageal Reflux Disease Completed NCT00872755 Phase 4
9 An 8-weeks, Multicenter, Single Arm, Non-comparative, Phase 4 Clinical Trial to Assess the Efficacy and Safety of Newrabell® Tab. at 10mg b.i.d in Patients With Refractory Reflux Esophagitis(rGERD) to the Prior Standard PPIs Regimen Completed NCT01860482 Phase 4 Newrabell® Tablet 10mg
10 A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR) Completed NCT02755753 Phase 4 Lansoprazole;Rebamipide;Rebamipide-placebo
11 An 8-week, Open Label, Multicentre Study to Assess the Efficacy of Esomeprazole 20 mg Once Daily in Subjects With Continuing Symptoms of Heartburn Following Treatment With a Previous Rabeprazole Completed NCT01397084 Phase 4 esomeprazole 20 mg
12 Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation (VISTAEXE) Completed NCT03116841 Phase 4 Vonoprazan
13 An Open Label, Multicentre Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed NCT00734097 Phase 4 Esomeprazole 40 mg
14 A Multicenter, Double-Blind, Randomized Trial of the Relationship of Intragastric Acid Control and Healing Status of Moderate and Severe Erosive Esophagitis After Treatment With Esomeprazole Magnesium (NEXIUM®) 10 mg and 40 mg Once Daily Completed NCT00206180 Phase 4 esomeprazole magnesium (oral medication)
15 An Open, Randomised Two Way Crossover Study Comparing the Effects of 20mg of Esomeprazole Administered Orally and Intravenously as a 3 Minute Injection on Basal and Pentagastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00626262 Phase 4 Esomeprazole
16 An Open, Randomised Two Way Crossover Study Comparing the Effects of 40mg of Esomeprazole Adminstered Orally and Intravenously as a 3 Minute Injection on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00625495 Phase 4 Esomeprazole;Esomeprazole
17 Effect of Rabeprazole and Lansoprazole on Reflux Esophagitis in Relation to CYP2C19 Genotype Status: A Prospective, Randomized, Multicenter Study Completed NCT01008696 Phase 4 Rabeprazole;Lansoprazole
18 CONFIRM - Confirmation of Superiority of Complete Remission Concept Versus Classical Healing Concept for Treatment of Patients With Erosive GERD Completed NCT00325676 Phase 4 Pantoprazole
19 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) Completed NCT00660660 Phase 4 Esomeprazole;Placebo
20 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) Completed NCT00628342 Phase 4 Esomeprazole;Esomeprazole;Placebo
21 Randomized, Placebo-Controlled Trial of Pantoprazole for Sleepiness Associated With Acid Reflux and Obstructive Sleep Disordered Breathing Completed NCT00307944 Phase 4 Pantoprazole
22 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia (BPD). Completed NCT00926276 Phase 4
23 Impact of Timing on the Efficacy of Omeprazole/Sodium Bicarbonate Zegerid 40 mg in Healing Reflux Esophagitis Completed NCT00693225 Phase 4 Omeprazole/sodium bicarbonate
24 PRISM: Determination of the Performance Characteristics of ReQuest (TradeMark) in Practice in the Stepped Down Management of GORD Completed NCT00261339 Phase 4 Pantoprazole
25 Determination of the Minimal Clinically Important Difference (MCID) of the Patient Orientated Self Assessment Scale ReQuest TradeMark in Patients Suffering From Endoscopically Confirmed Gastroesophageal Reflux Disease (GERD), Grade A-D According to Los Angeles Classification Treated With Pantoprazole 40 mg o.d. or Placebo o.d. Over One Week. Completed NCT00246909 Phase 4 Pantoprazole
26 A Non Interventional Post Authorization Safety Study (PASS) On The Rabeprazole's Administration To Adults With Gastro-Oesophageal Reflux Disease (GORD) Completed NCT00216489 Phase 4 rabeprazole sodium
27 A Phase 4, Open-Label Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole Completed NCT02351960 Phase 4 Dexlansoprazole
28 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4 mosapride for the first month and placebo for the 2nd month;placebo for the first and mosapride for the second month
29 The Rabeprazole and Esomeprazole Reflux Assessment Trial (TREAT) Completed NCT00464308 Phase 4 Esomeprazole;Rabeprazole;Esomeprazole
30 Phase IV Non Comparative Study of the Impact of Dietary Fiber Deficiency Correction Using Mucofalk® on Clinical Features and Motor Function of the Esophagus in Patients With Non-erosive Gastroesophageal Reflux Disease Completed NCT01882088 Phase 4 Mucofalk
31 Role of Bronchoalveolar Lavage Pepsin Assay in Wheezy Infants Completed NCT02685436 Phase 4 Omeprazole and domperidone
32 A Randomized, Two-way Crossover Study of the Effects of a Single Dose of Rabeprazole or Pantoprazole on 24-hour Intragastric Acidity and Esophageal Acid Exposure in GERD Patients With a History of Nocturnal Heartburn Completed NCT00237367 Phase 4 rabeprazole and pantoprazole
33 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease. An Open, Single Arm, Long-term Study Completed NCT01135368 Phase 4 Lansoprazole
34 A Phase III, Multicentre, Randomized, Double-blind Parallel-group Study to Evaluate the Safety and Clinical Outcome of Once Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years of Age, Inclusive. Completed NCT00228527 Phase 4 Esomeprazole (Nexium)
35 Ivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan Completed NCT02241044 Phase 4
36 The Influence of CYP2C19 Genetic Polymorphism and Dosage of Rabeprazole on the Accuracy of Proton-Pump Inhibitor Testing in Chinese Patients With Gastroesophageal Reflux Disease Completed NCT00354757 Phase 4 rabeprazole
37 Efficacy of Zinc L-carnosine (Hepilor®) in Maintaining Remission of Gastroesophageal Reflux Disease: a Randomised, Double-blind, Placebo-controlled Study Recruiting NCT03467438 Phase 4 Zinc-l-carnosine
38 Use of Metoclopramide for the Prevention of Gastroesophageal Reflux in Premature Infants Followed in an Outpatient Kangaroo Mother Care Clinic Before 40 Weeks of Gestational Age: A Randomized Controlled Trial Recruiting NCT02907632 Phase 4 Metoclopramide;Placebo
39 Effective Mechanisms of Wu-Chu-Yu Tang on Gastroesophageal Disorder Recruiting NCT04118647 Phase 4 Wu-Chu-Yu tang
40 Effect of Indobufen Versus Aspirin on Gastric Acid Secretion and Gastroesophageal Reflux in Patients With Coronary Heart Disease and Gastroesophageal Reflux Disease Undergoing Dual Antiplatelet Therapy: a Prospective, Randomized, Double-blind, Double-dummy, Positive Drug Parallel Control Clinical Trials Not yet recruiting NCT04129008 Phase 4 Indobufen and aspirin mimetic;Aspirin and indobufen mimetic
41 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4 Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
42 Proton Pump Inhibitor (PPI's) and Selective Serotonin Reuptake Inhibitor Therapy (SSRI's) for the Management of Non Cardiac Chest Pain (NCCP) Terminated NCT02825342 Phase 4 Citalopram
43 The Effect of Dexilant Treatment on Esophageal Hypersensitivity in GERD Related Non Cardiac Chest Pain Patients Withdrawn NCT01637571 Phase 4 Dexilant;Dexilant Placebo
44 A Prospective Randomized Trial Comparing Laparoscopic Nissen Against Anterior Partial Fundoplication in Treating Gastroesophageal Reflux Disease Among Chinese Patients Unknown status NCT00480285 Phase 3
45 Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine - Completed NCT00229424 Phase 3 Lafutidine;Famotidine
46 A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of Esomeprazole 20 mg Once Daily Oral Administration With Omeprazole 10 mg and Esomeprazole 10 mg Once Daily Oral Administration in Maintenance Treatment in Patients With Healed Reflux Esophagitis Completed NCT00634114 Phase 3 Esomeprazole;Esomeprazole;Omeprazole
47 A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of Esomeprazole 20 mg and 40 mg Once Daily Oral Administration With Omeprazole 20 mg Once Daily Oral Administration in Patients With Reflux Esophagitis Completed NCT00633932 Phase 3 Esomeprazole;Esomeprazole;Omeprazole
48 Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis Completed NCT00770913 Phase 2, Phase 3 E3810;E3810;E3810
49 Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs). Completed NCT00171483 Phase 3 Tegaserod
50 Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs). Completed NCT00171418 Phase 3 Tegaserod

Search NIH Clinical Center for Peptic Esophagitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aluminum carbonate
Aluminum Hydroxide
Aluminum Hydroxide / Magnesium Hydroxide
Aluminum Hydroxide Gel
aluminum hydroxide, dried (USP)
basic aluminum carbonate gel
Calcium Carbonate
CALCIUM CARBONATE 1 g in 1 g ORAL POWDER
Calcium gluceptate
Calcium Glycerophosphate
Cimetidine
Cimetidine Hydrochloride
dihydroxyaluminum sodium carbonate
Famotidine
Magnesium Hydroxide
MILK OF MAGNESIA
Nizatidine

Cochrane evidence based reviews: esophagitis, peptic

Genetic Tests for Peptic Esophagitis

Anatomical Context for Peptic Esophagitis

MalaCards organs/tissues related to Peptic Esophagitis:

40
Liver, Testes, Bone, Colon, Heart, Lung, Smooth Muscle

Publications for Peptic Esophagitis

Articles related to Peptic Esophagitis:

(show top 50) (show all 3593)
# Title Authors PMID Year
1
Functional Outcomes of Delta-Shaped Anastomosis After Laparoscopic Distal Gastrectomy. 61
32026335 2020
2
Alport-leiomyomatosis syndrome requiring subtotal esophagectomy for refractory gastroesophageal reflux disease after childhood partial esophagogastrectomy: a case report. 61
31758390 2020
3
Association between visceral abdominal obesity and long-segment Barrett's esophagus in a Japanese population. 61
31667587 2020
4
Laparoscopic Single Anastomosis Sleeve Ileal (SASI) Bypass for Patients With Morbid Obesity: Technical Description and Short-term Outcomes. 61
32032329 2020
5
Sudden appearance of widespread esophageal squamous papilloma with reflux esophagitis. 61
32036041 2020
6
Laparoscopic Roux-en-Y Gastric Bypass After Gastroesophageal Reflux Disease Surgical Procedure: Analysis of 85 Consecutive Patients with Pre- and Post-Operative Endoscopy Control. 61
31368842 2020
7
Role of Multimodality Imaging in Gastroesophageal Reflux Disease and Its Complications, with Clinical and Pathologic Correlation. 61
31917657 2020
8
Localization of Helicobacter pylori gastritis and the relation of existing histopathological features with reflux esophagitis. 61
31865819 2020
9
In Barrett's Epithelial Cells, Weakly Acidic Bile Salt Solutions Cause Oxidative DNA Damage with Response and Repair Mediated by p38. 61
31984785 2020
10
Size-dependent differences in the proximal remnant stomach: how much does a small remnant stomach after subtotal gastrectomy work? 61
31950274 2020
11
Efficacy of Celiac Branch Preservation in Billroth-Ⅰ Reconstruction After Laparoscopy-Assisted Distal Gastrectomy. 61
31425872 2020
12
Risk of hemorrhage and stricture significantly increases in elderly patients with proton pump inhibitor (PPI)-resistant reflux esophagitis. 61
31679094 2020
13
Bile Reflux is a Common Finding in the Gastric Pouch After One Anastomosis Gastric Bypass. 61
31853864 2019
14
Endoscopic or Surgical Myotomy in Patients with Idiopathic Achalasia. 61
31800987 2019
15
Upper gastrointestinal involvement in systemic sclerosis: Findings in a real-life setting. 61
31798729 2019
16
Association between skeletal muscle attenuation and gastroesophageal reflux disease: A health check-up cohort study. 61
31882910 2019
17
Prevalence and Predictive Factors of Histopathological Complications in Children with Esophageal Atresia. 61
30566986 2019
18
Isorhamnetin alleviates esophageal mucosal injury in a chronic model of reflux esophagitis. 61
31586635 2019
19
The impact of cervical lymph node dissection on acid and duodenogastroesophageal reflux after intrathoracic esophagogastrostomy following transthoracic esophagectomy. 61
31218418 2019
20
Comparison of three digestive tract reconstruction methods for the treatment of Siewert II and III adenocarcinoma of esophagogastric junction: a prospective, randomized controlled study. 61
31810484 2019
21
The Clinical Efficacy of a Pure Alginate Formulation (Lamina G) for Controlling Symptoms in Individuals with Reflux Symptoms: A Randomized Clinical Study. 61
30970442 2019
22
Is the Diagnostic Trial with Proton Pump Inhibitors Reasonable for School Age Children with Gastroesophageal Reflux Symptoms? 61
31777716 2019
23
Activin A-mediated epithelial de-differentiation contributes to injury repair in an in vitro gastrointestinal reflux model. 61
31369967 2019
24
Chronic Obstructive Pulmonary Disease and the Risk of Esophagitis, Barrett's Esophagus, and Esophageal Adenocarcinoma: A Primary Care Case-Control Study. 61
31008868 2019
25
Laparoscopic One Anastomosis Gastric Bypass Versus Laparoscopic One Anastomosis Gastric Bypass with Braun Anastomosis: What's Better? 61
31017503 2019
26
Associations between the severity of reflux esophagitis in children and changes in oxidative stress, serum inflammation, vasoactive intestinal peptide and motilin. 61
31602227 2019
27
Relationship between Barrett's esophagus and colonic diseases: a role for colonoscopy in Barrett's surveillance. 61
31240437 2019
28
Prevalence of and Risk Factors for Diseases in Korean Americans and Native Koreans Undergoing Health Checkup. 61
31639887 2019
29
Upper Gastrointestinal Disease Influences the Occurrence of Inflammatory Bowel Disease. 61
31776861 2019
30
Is Roux-en-Y or Billroth-II reconstruction the preferred choice for gastric cancer patients undergoing distal gastrectomy when Billroth I reconstruction is not applicable? A meta-analysis. 61
31770192 2019
31
Peroral endoscopic myotomy for achalasia: a prospective multicenter study in Japan. 61
31759035 2019
32
Long-term effect of Helicobacter pylori eradication on prevalence of reflux esophagitis. 61
31111517 2019
33
Proton Pump Inhibitors and Radiofrequency Ablation for Treatment of Barrett's Esophagus. 61
31644405 2019
34
Interaction Between Ethnicity and Helicobacter pylori Infection in the Occurrence of Reflux Disease. 61
31651573 2019
35
Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis. 61
31119492 2019
36
History of gastroesophageal reflux disease in patients with suspected coronary artery disease. 61
30993440 2019
37
Comparison of Functional Outcomes between Functional Jejunal Interposition and Conventional Roux-en-Y Esophagojejunostomy after Total Gastrectomy for Gastric Cancer. 61
31614348 2019
38
Risk factors for reflux esophagitis after eradication of Helicobacter pylori. 61
31577454 2019
39
Comparison of Billroth I, Billroth II, and Roux-en-Y reconstructions after distal gastrectomy according to functional recovery: a meta-analysis. 61
31539143 2019
40
Surgical outcomes and risk assessment for anastomotic complications after laparoscopic proximal gastrectomy with double-flap technique for upper-third gastric cancer. 61
30838469 2019
41
Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan. 61
31178490 2019
42
Clinical prediction model for tumor progression in Barrett's esophagus. 61
30456503 2019
43
Association Between Helicobacter pylori Infection and Short-segment/Long-segment Barrett's Esophagus in a Japanese Population: A Large Cross-Sectional Study. 61
31524650 2019
44
Long-limb Roux-en-Y Reconstruction after Subtotal Gastrectomy to Treat Severe Diabetic Gastroparesis. 61
31598378 2019
45
Changes in Clock Genes Expression in Esophagus in Rat Reflux Esophagitis. 61
30815822 2019
46
Another Case of Reflux Esophagitis? 61
30965028 2019
47
A meta-analysis of comparison of proximal gastrectomy with double-tract reconstruction and total gastrectomy for proximal early gastric cancer. 61
31438918 2019
48
Esophagitis in Pediatric Esophageal Atresia: Acid May Not Always Be the Issue. 61
30921254 2019
49
[Prevention, screening and check-ups in gastroenterology]. 61
31454840 2019
50
Effect of Peroral Endoscopic Myotomy vs Pneumatic Dilation on Symptom Severity and Treatment Outcomes Among Treatment-Naive Patients With Achalasia: A Randomized Clinical Trial. 61
31287522 2019

Variations for Peptic Esophagitis

Expression for Peptic Esophagitis

Search GEO for disease gene expression data for Peptic Esophagitis.

Pathways for Peptic Esophagitis

Pathways related to Peptic Esophagitis according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.2 PTGS2 IL6 IL1B ALB
2
Show member pathways
12.19 PTGS2 IL6 IL1B CXCL8
3 12.15 OCLN IL6 IL1B CXCL8
4
Show member pathways
12.1 S100A8 PTGS2 IL6 IL1B CXCL8
5
Show member pathways
12.07 PTGS2 IL6 IL1B CXCL8
6 11.88 IL6 CDX2 CDX1 ALB
7 11.81 PTGS2 IL6 IL1B CXCL8
8 11.76 PTGS2 IL6 IL1B CXCL8
9 11.74 IL6 IL1B CXCL8
10 11.66 IL6 IL1B CXCL8
11 11.63 IL6 IL1B CXCL8
12 11.53 IL6 IL1B CXCL8
13 11.47 IL6 IL1B CXCL8
14 11.41 PTGS2 IL6 IL1B CCL26
15 11.39 PTGS2 IL6 CXCL8
16 11.37 IL6 IL1B CXCL8
17 11.31 IL6 IL1B CDX2
18
Show member pathways
11.26 PTGS2 IL6 IL1B CXCL8
19 10.95 PTGS2 IL6 IL1B CXCL8
20 10.78 PTGS2 IL6 CXCL8
21 9.5 HRH2 GAST ATP4A

GO Terms for Peptic Esophagitis

Cellular components related to Peptic Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 S100A8 IL6 IL1B GAST CXCL8 CCL26

Biological processes related to Peptic Esophagitis according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.89 IL6 IL1B HRH2 CXCL8 CCL26
2 cellular response to tumor necrosis factor GO:0071356 9.62 TRPV1 OCLN CXCL8 CCL26
3 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.55 ATP4A ATP12A
4 sodium ion export across plasma membrane GO:0036376 9.54 ATP4A ATP12A
5 positive regulation of nitric oxide biosynthetic process GO:0045429 9.54 TRPV1 PTGS2 IL1B
6 cellular potassium ion homeostasis GO:0030007 9.52 ATP4A ATP12A
7 positive regulation of neuroinflammatory response GO:0150078 9.51 IL6 IL1B
8 regulation of neuroinflammatory response GO:0150077 9.48 PTGS2 IL6
9 positive regulation of prostaglandin biosynthetic process GO:0031394 9.46 PTGS2 IL1B
10 regulation of somitogenesis GO:0014807 9.43 CDX2 CDX1
11 positive regulation of fever generation GO:0031622 9.4 PTGS2 IL1B
12 positive regulation of vascular endothelial growth factor production GO:0010575 9.33 PTGS2 IL6 IL1B
13 fever generation GO:0001660 9.26 TRPV1 IL1B
14 neutrophil chemotaxis GO:0030593 9.26 S100A8 IL1B CXCL8 CCL26
15 inflammatory response GO:0006954 9.17 TRPV1 S100A8 PTGS2 IL6 IL1B CXCL8

Molecular functions related to Peptic Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.46 IL6 IL1B CXCL8 CCL26
2 sodium:potassium-exchanging ATPase activity GO:0005391 9.26 ATP4A ATP12A
3 potassium-transporting ATPase activity GO:0008556 8.96 ATP4A ATP12A
4 potassium:proton exchanging ATPase activity GO:0008900 8.62 ATP4A ATP12A

Sources for Peptic Esophagitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....